Supply Chain Research

Price deflation is a continuing challenge for U.S. pharmaceutical companies, driven in part by increased competition from generic drug makers. Teva and Mylan both cut their full year guidance as a result, while Dr. Reddy’s missed analysts’ expectations. U.S. import data has shown average values per gram have fallen for 11 straight months through June, with a 20% drop. Cardiovascular treatments, including statins, saw the heaviest decline at 37%. Worryingly oncology treatments – previously a rising price product group – fell 4%. The outliers were anticonvulsants, which climbed in both vol...